Immune Pharma (IMNP): Celator Acquisition Highlights Ceplene's Value in AML

FBR Capital analyst, Vernon Bernardino, thinks that Immune Pharmaceuticals (NASDAQ: IMNP) is currently undervalued when considering the collective value of its clinical-stage assets. Following Jazz Pharmaceuticals' (JAZZ) recent announcement of its $1.5B acquisition of Celator Pharmaceuticals (CPXX) for Vyxeos, the latter's Phase III stage product candidate for acute myeloid leukemia (AML). The analyst thinks Ceplene, an IMNP asset already approved in the EU and Israel as a treatment for maintenance of complete response (CR) in patients with AML, alone is undervalued.

No change to Outperform rating or $3 PT.

For an analyst ratings summary and ratings history on Immune Pharmaceuticals click here. For more ratings news on Immune Pharmaceuticals click here.

Shares of Immune Pharmaceuticals closed at $0.37 yesterday.

You May Also Be Interested In

• Deutsche Bank Upgrades Target Hospitality (TH) to Buy
• Benchmark Reiterates Buy Rating on Alibaba (BABA) on Solid Q1 Earnings Beat
• Oppenheimer Reiterates Outperform Rating on NVIDIA (NVDA) Into EPS